Silvain J, et al. - In this substudy of the ATOLL trial, researchers compared the peri-procedural biomarkers of coagulation and platelet activation among 129 ST-segment elevation myocardial infarction (STEMI) patients who had percutaneous coronary intervention (PCI) and were randomly allocated to intravenous enoxaparin (n = 58) or unfractionated heparin (UFH; n = 71). Findings demonstrated that, enoxaparin vs UFH more frequently achieved therapeutic levels during primary PCI. More frequent ischemic events were documented in relation to higher level of thrombin generation measured at the end of the PCI procedure. Results showed correlation of activated partial thromboplastin time ratio, anti-Xa activity, von Willebrand factor antigen, prothrombin fragment 1 + 2 (F1 + 2), thrombin–antithrombin complex (TAT), tissue factor pathway inhibitor and soluble CD40 ligand, with 1-month clinical outcomes.